MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phas…
Biotechnology
CH, Zug [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 20.42 | 62.13 | 51.59 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -22.86 | 22.97 | 29.78 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 4.70 | 8.66 | 8.27 | |
| Cash | 2.40 | 8.73 | 8.53 | |
| Capex | 28.83 | < 0.005 | < 0.005 | |
| Free Cash Flow | -14.82 | -0.24 | -0.21 | |
| Revenue | inf | 0.00 | < 0.005 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | inf | 0.00 | 0.83 | |
| Operating Margin | inf | 0.00 | -761.42 | |
| ROA | -71.61 | -0.02 | -0.01 | |
| ROE | -67.97 | -0.03 | -0.02 | |
| ROIC | -20.50 | -0.04 | -0.03 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of MLTX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of MLTX is permitted for members.
6
Leverage & Liquidity